Although the heterologous strategy cannot increase the overall frequency and level of activation of CD8+ T cells in patients with breakthrough infection, it may still decrease the patient’s viral load by expanding the memory and effector pool of CD8+ T cells. The gene discussed is CD8A; the disease is infection.